Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.

Bone Neoplasms / drug therapy Canada Cost-Benefit Analysis Humans Male Prostatic Neoplasms, Castration-Resistant / drug therapy Quality-Adjusted Life Years
bone metastasis breast cancer cost-effectiveness denosumab pamidronate prostate cancer zoledronate

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
13 05 2021
Historique:
received: 28 03 2021
revised: 23 04 2021
accepted: 06 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 25 9 2021
Statut: epublish

Résumé

A cost-utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (

Identifiants

DOI: 10.3390/curroncol28030171 PMID: 34068083 PMC: PMC8161812
pubmed: 34068083
pii: curroncol28030171
doi: 10.3390/curroncol28030171
pmc: PMC8161812
doi:

Banques de données

ClinicalTrials.gov
['NCT02721433']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1847-1856

Subventions

Organisme : CIHR
Pays : Canada

Références

Value Health. 2011 Jul-Aug;14(5):721-31
pubmed: 21839411
MDM Policy Pract. 2019 Apr 13;4(1):2381468319842532
pubmed: 31245606
J Clin Oncol. 2017 Dec 10;35(35):3978-3986
pubmed: 29035643
J Med Econ. 2013;16(1):19-29
pubmed: 22870908
J Med Econ. 2012;15(4):712-23
pubmed: 22409231
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Curr Oncol. 2012 Oct;19(5):259-68
pubmed: 23144574
Eur J Health Econ. 2010 Aug;11(4):427-34
pubmed: 20473703
J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358
pubmed: 27732330
J Clin Oncol. 2017 Dec 10;35(35):3949-3955
pubmed: 29023215
J Bone Oncol. 2020 Nov 10;26:100339
pubmed: 33294318
Support Care Cancer. 2021 Feb;29(2):925-943
pubmed: 32535678
Clin Ther. 2012 Jun;34(6):1334-49
pubmed: 22578308
Clin Breast Cancer. 2012 Aug;12(4):247-58
pubmed: 22694824
Eur J Cancer. 2021 Jan;142:132-140
pubmed: 33023785
J Manag Care Pharm. 2011 Oct;17(8):621-43
pubmed: 21942303

Auteurs

Megan M Tu (MM)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

Mark Clemons (M)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.

Carol Stober (C)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Ahwon Jeong (A)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Lisa Vandermeer (L)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Mihaela Mates (M)

Division of Medical Oncology, Cancer Centre of Southeastern Ontario and Queen's University, Kingston, ON K7L 5P9, Canada.

Phillip Blanchette (P)

Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario, London, ON N6A 5W9, Canada.

Anil Abraham Joy (AA)

Division of Medical Oncology, Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada.

Olexiy Aseyev (O)

Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON P7B 6V4, Canada.

Gregory Pond (G)

Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.

Dean Fergusson (D)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Terry L Ng (TL)

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.

Kednapa Thavorn (K)

Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
ICES, University of Ottawa, Ottawa, ON K1Y 4E9, Canada.
ORCID: 0000-0003-4738-8447

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies ostéomusculaires › Maladies osseuses › Tumeurs osseuses › Cost-Effectiveness Analysis of 12-Versus...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › Canada › Cost-Effectiveness Analysis of 12-Versus...
questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Cost-Effectiveness Analysis of 12-Versus...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cost-Effectiveness Analysis of 12-Versus...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Cost-Effectiveness Analysis of 12-Versus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Espérance de vie › Années de vie ajustées sur la qualité › Cost-Effectiveness Analysis of 12-Versus...